These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37013843)

  • 1. Dendritic cell-based immunotherapy: a potential player in oral cancer therapeutics.
    Dwivedi R; Pandey R; Chandra S; Mehrotra D
    Immunotherapy; 2023 Apr; 15(6):457-469. PubMed ID: 37013843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cell biology and its role in tumor immunotherapy.
    Wang Y; Xiang Y; Xin VW; Wang XW; Peng XC; Liu XQ; Wang D; Li N; Cheng JT; Lyv YN; Cui SZ; Ma Z; Zhang Q; Xin HW
    J Hematol Oncol; 2020 Aug; 13(1):107. PubMed ID: 32746880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cell based vaccines: progress in immunotherapy studies for prostate cancer.
    Ragde H; Cavanagh WA; Tjoa BA
    J Urol; 2004 Dec; 172(6 Pt 2):2532-8. PubMed ID: 15538202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of dendritic cell-based vaccine using high hydrostatic pressure for non-small cell lung cancer immunotherapy.
    Hradilova N; Sadilkova L; Palata O; Mysikova D; Mrazkova H; Lischke R; Spisek R; Adkins I
    PLoS One; 2017; 12(2):e0171539. PubMed ID: 28187172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic-tumor cell hybrids induce tumor-specific immune responses more effectively than the simple mixture of dendritic and tumor cells.
    Pinho MP; Sundarasetty BS; Bergami-Santos PC; Steponavicius-Cruz K; Ferreira AK; Stripecke R; Barbuto JA
    Cytotherapy; 2016 Apr; 18(4):570-80. PubMed ID: 26971685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic-tumor fusion cells in cancer immunotherapy.
    Takakura K; Kajihara M; Ito Z; Ohkusa T; Gong J; Koido S
    Discov Med; 2015 Mar; 19(104):169-74. PubMed ID: 25828520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eliciting cytotoxic T lymphocytes against human laryngeal cancer-derived antigens: evaluation of dendritic cells pulsed with a heat-treated tumor lysate and other antigen-loading strategies for dendritic-cell-based vaccination.
    Wei FQ; Sun W; Wong TS; Gao W; Wen YH; Wei JW; Wei Y; Wen WP
    J Exp Clin Cancer Res; 2016 Jan; 35():18. PubMed ID: 26795730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic cell gene therapy.
    Onaitis M; Kalady MF; Pruitt S; Tyler DS
    Surg Oncol Clin N Am; 2002 Jul; 11(3):645-60. PubMed ID: 12487060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalized dendritic cell-based tumor immunotherapy.
    Janikashvili N; Larmonier N; Katsanis E
    Immunotherapy; 2010 Jan; 2(1):57-68. PubMed ID: 20161666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current State of Dendritic Cell-Based Immunotherapy: Opportunities for
    Huber A; Dammeijer F; Aerts JGJV; Vroman H
    Front Immunol; 2018; 9():2804. PubMed ID: 30559743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miRNA-5119 regulates immune checkpoints in dendritic cells to enhance breast cancer immunotherapy.
    Zhang M; Shi Y; Zhang Y; Wang Y; Alotaibi F; Qiu L; Wang H; Peng S; Liu Y; Li Q; Gao D; Wang Z; Yuan K; Dou FF; Koropatnick J; Xiong J; Min W
    Cancer Immunol Immunother; 2020 Jun; 69(6):951-967. PubMed ID: 32076794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
    Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
    Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential approaches for more successful dendritic cell-based immunotherapy.
    Chiang CL; Balint K; Coukos G; Kandalaft LE
    Expert Opin Biol Ther; 2015 Apr; 15(4):569-82. PubMed ID: 25553913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical application of cancer immunotherapy based on naturally circulating dendritic cells.
    Bol KF; Schreibelt G; Rabold K; Wculek SK; Schwarze JK; Dzionek A; Teijeira A; Kandalaft LE; Romero P; Coukos G; Neyns B; Sancho D; Melero I; de Vries IJM
    J Immunother Cancer; 2019 Apr; 7(1):109. PubMed ID: 30999964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses.
    Silva M; Silva Z; Marques G; Ferro T; Gonçalves M; Monteiro M; van Vliet SJ; Mohr E; Lino AC; Fernandes AR; Lima FA; van Kooyk Y; Matos T; Tadokoro CE; Videira PA
    Oncotarget; 2016 Jul; 7(27):41053-41066. PubMed ID: 27203391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquisition and Presentation of Tumor Antigens by Dendritic Cells.
    Bonaccorsi I; Campana S; Morandi B; Ferlazzo G
    Crit Rev Immunol; 2015; 35(5):349-64. PubMed ID: 26853848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity.
    Hong S; Li H; Qian J; Yang J; Lu Y; Yi Q
    Clin Exp Immunol; 2012 Nov; 170(2):167-77. PubMed ID: 23039887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trial watch: Dendritic cell (DC)-based immunotherapy for cancer.
    Laureano RS; Sprooten J; Vanmeerbeerk I; Borras DM; Govaerts J; Naulaerts S; Berneman ZN; Beuselinck B; Bol KF; Borst J; Coosemans A; Datsi A; Fučíková J; Kinget L; Neyns B; Schreibelt G; Smits E; Sorg RV; Spisek R; Thielemans K; Tuyaerts S; De Vleeschouwer S; de Vries IJM; Xiao Y; Garg AD
    Oncoimmunology; 2022; 11(1):2096363. PubMed ID: 35800158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous activation of T helper function can augment the potency of dendritic cell-based cancer immunotherapy.
    Teramoto K; Ohshio Y; Fujita T; Hanaoka J; Kontani K
    J Cancer Res Clin Oncol; 2013 May; 139(5):861-70. PubMed ID: 23411688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer.
    Versteven M; Van den Bergh JMJ; Marcq E; Smits ELJ; Van Tendeloo VFI; Hobo W; Lion E
    Front Immunol; 2018; 9():394. PubMed ID: 29599770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.